Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 18/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 17/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 16/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 15/20 | 0.68 |
| ▸ | TSHR | P16473 | 13/20 | 0.68 |
| ▸ | LMNA | P02545 | 12/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 10/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.68 |
| ▸ | HPGD | P15428 | 4/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
| ▸ | CLK4 | Q9HAZ1 | 13/20 | 0.64 |
| ▸ | USP2 | O75604 | 10/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.64 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13043863 | 0.84 | MAP4K4 (0.73) | MAP4K4CYP1A2CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL15587269 | 0.83 | MAP4K4 (1.00) | MAP4K4CYP1A2CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL31060425 | 0.83 | MAP4K4 (1.00) | MAP4K4CYP1A2CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL3733304 | 0.83 | MAP4K4 (0.71) | MAP4K4CYP1A2CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL180943 | 0.81 | ENPP1 (0.55) | MAP4K4TSHRHSD17B10MAPK1CLK4 | |
| SCHEMBL18970603 | 0.81 | MAP4K4 (0.60) | MAP4K4CYP1A2CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL27748892 | 0.78 | PDE4A (0.50) | MAP4K4CYP1A2CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL6997835 | 0.78 | PLAU (0.68) | MAP4K4CYP1A2CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL27527937 | 0.76 | PLG (0.53) | MAP4K4CYP1A2CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL18712270 | 0.74 | PDE4A (0.45) | MAP4K4CYP1A2CYP3A4CYP2C19CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1656345-B1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2013-10-16 | — | — | EP | disclosed |
| CN-1871215-B | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL MYERS SQUIBB CO | 2011-06-08 | — | — | CN | disclosed |
| US-7829571-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-11-09 | — | — | US | disclosed |
| US-20090124668-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2009-05-14 | — | — | US | disclosed |
| US-7482335-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-27 | — | — | US | disclosed |
| US-7378409-B2 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| EP-1656138-A4 | SUBSTITUTED CYCLOALKYAMINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2007-04-18 | — | — | EP | disclosed |
| US-20070032526-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CARTER PEROY H | 2007-02-08 | — | — | US | disclosed |
| US-7163937-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-16 | — | — | US | disclosed |
| CN-1871215-A | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL MYERS SQUIBB CO (US) | 2006-11-29 | — | — | CN | disclosed |
| EP-1656138-A2 | SUBSTITUTED CYCLOALKYAMINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Company (US) | 2006-05-17 | — | — | EP | disclosed |
| EP-1656345-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Company (US) | 2006-05-17 | — | — | EP | disclosed |
| WO-2005020899-A2 | SUBSTITUTED CYCLOALKYAMINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2005021500-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-10 | — | — | US | disclosed |
| US-20050054627-A1 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032526-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCL2, CCR1 | MAP4K4 1458/4885CYP1A2 3692/4885CYP3A4 4063/4885 |
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCR2 | MAP4K4 2871/4885CYP1A2 2798/4885CYP3A4 3690/4885 |
| US-20090124668-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCL11, CCL2, CCR1 | MAP4K4 1458/4885CYP1A2 3692/4885CYP3A4 4063/4885 |
| US-20050054627-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCL2, CCR1 | MAP4K4 1458/4885CYP1A2 3692/4885CYP3A4 4063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.